Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

TARGETING ALDEHYDE DEHYDROGENASE 2: NEW THERAPEUTIC OPPORTUNITIES

Texto completo
Autor(es):
Chen, Che-Hong [1] ; Batista Ferreira, Julio Cesar [1] ; Gross, Eric R. [1] ; Mochly-Rosen, Daria [2]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Stanford Univ, Sch Med, Dept Anesthesiol, Stanford, CA 94305 - USA
[2] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 - USA
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: Physiological Reviews; v. 94, n. 1, p. 1-34, JAN 2014.
Citações Web of Science: 160
Resumo

A family of detoxifying enzymes called aldehyde dehydrogenases (ALDHs) has been a subject of recent interest, as its role in detoxifying aldehydes that accumulate through metabolism and to which we are exposed from the environment has been elucidated. Although the human genome has 19 ALDH genes, one ALDH emerges as a particularly important enzyme in a variety of human pathologies. This ALDH, ALDH2, is located in the mitochondrial matrix with much known about its role in ethanol metabolism. Less known is a new body of research to be discussed in this review, suggesting that ALDH2 dysfunction may contribute to a variety of human diseases including cardiovascular diseases, diabetes, neurodegenerative diseases, stroke, and cancer. Recent studies suggest that ALDH2 dysfunction is also associated with Fanconi anemia, pain, osteoporosis, and the process of aging. Furthermore, an ALDH2 inactivating mutation (termed ALDH2{*}2) is the most common single point mutation in humans, and epidemiological studies suggest a correlation between this inactivating mutation and increased propensity for common human pathologies. These data together with studies in animal models and the use of new pharmacological tools that activate ALDH2 depict a new picture related to ALDH2 as a critical health-promoting enzyme. (AU)

Processo FAPESP: 12/05765-2 - Contribuição da enzima aldeído desidrogenase 2 na progressão da insuficiência cardíaca
Beneficiário:Julio Cesar Batista Ferreira
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores